Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $78
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Boston Scientific (NYSE:BSX) and raises the price target from $70 to $78.
April 26, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Boston Scientific and raises the price target from $70 to $78.
The upgrade in the price target by Barclays reflects a positive outlook on Boston Scientific's future performance. This is likely to be viewed favorably by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100